» Articles » PMID: 37639849

Messenger RNA Chromatographic Purification: Advances and Challenges

Overview
Journal J Chromatogr A
Publisher Elsevier
Specialty Chemistry
Date 2023 Aug 28
PMID 37639849
Authors
Affiliations
Soon will be listed here.
Abstract

Messenger RNA (mRNA) technologies have shown great potential in prophylactic vaccines and therapeutic medicines due to their adaptability, rapidity, efficacy, and safety. The purity of mRNA determines the efficacy and safety of mRNA drugs. Though chromatographic technologies are currently employed in mRNA purification, they are facing challenges, mainly arising from the large size, relatively simple chemical composition, instability, and high resemblance of by-products to the target mRNA. In this review, we will first make a comprehensive analysis of physiochemical properties differences between mRNA and proteins, then the major challenges facing in mRNA purification and general considerations are highlighted. A detailed summary of the state-of-arts in mRNA chromatographic purification will be provided, which are mainly classified into physicochemical property-based (size, charge, and hydrophobicity) and chemical structure-based (phosphate backbone, bases, cap structure, and poly A tail) technologies. Efforts in eliminating dsRNA byproducts via post in vitro transcript (IVT) purification and by manipulating the IVT process to reduce the generation of dsRNA are highlighted. Finally, a brief summary of the current status of chromatographic purification of the emerging circular mRNA (circRNA) is provided. We hope this review will provide some useful guidance for the Quality by Design (QbD) of mRNA downstream process development.

Citing Articles

The Impact of COVID-19 on RNA Therapeutics: A Surge in Lipid Nanoparticles and Alternative Delivery Systems.

Parvin N, Mandal T, Joo S Pharmaceutics. 2024; 16(11).

PMID: 39598489 PMC: 11597542. DOI: 10.3390/pharmaceutics16111366.


Trinucleotide cap analogs with triphosphate chain modifications: synthesis, properties, and evaluation as mRNA capping reagents.

Warminski M, Depaix A, Ziemkiewicz K, Spiewla T, Zuberek J, Drazkowska K Nucleic Acids Res. 2024; 52(18):10788-10809.

PMID: 39248095 PMC: 11472058. DOI: 10.1093/nar/gkae763.


Trinucleotide mRNA Cap Analogue 6-Benzylated at the Site of Posttranscriptional A Mark Facilitates mRNA Purification and Confers Superior Translational Properties In Vitro and In Vivo.

Warminski M, Trepkowska E, Smietanski M, Sikorski P, Baranowski M, Bednarczyk M J Am Chem Soc. 2024; 146(12):8149-8163.

PMID: 38442005 PMC: 10979456. DOI: 10.1021/jacs.3c12629.


Digital Twin Fundamentals of mRNA Transcription in Variable Scale Toward Autonomous Operation.

Hengelbrock A, Schmidt A, Strube J ACS Omega. 2024; 9(7):8204-8220.

PMID: 38405539 PMC: 10882708. DOI: 10.1021/acsomega.3c08732.


Comprehensive Impurity Profiling of mRNA: Evaluating Current Technologies and Advanced Analytical Techniques.

Camperi J, Lippold S, Ayalew L, Roper B, Shao S, Freund E Anal Chem. 2024; 96(9):3886-3897.

PMID: 38377434 PMC: 10918618. DOI: 10.1021/acs.analchem.3c05539.